enGene Therapeutics (ENGN) grants director 31,000 stock options

Rhea-AI Filing Summary

enGene Therapeutics Inc. director Gerald A. Brunk received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and were awarded at no cost.

The options expire on June 16, 2036. According to the disclosure, the option vests fully on the earlier of the first anniversary of the June 9, 2026 vesting commencement date or the company’s 2027 annual meeting of shareholders. Following this grant, Brunk holds options for 31,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BRUNK GERALD A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 31,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 31,000 options Exercise price: $1.75 per share Underlying shares: 31,000 common shares +2 more

5 metrics

Option grant size 31,000 options Stock Option (Right to Buy) granted to director

Exercise price <money>$1.75</money> per share Conversion or exercise price of options

Underlying shares 31,000 common shares Underlying security for the stock options

Total options after grant 31,000 options Total shares following transaction for this option award

Option expiration <date>June 16, 2036</date> Expiration date of the stock options

Key Terms

Stock Option (Right to Buy), vesting commencement date, annual meeting of shareholders, Common Shares

4 terms

Stock Option (Right to Buy) financial

"Security title is listed as "Stock Option (Right to Buy)" for the grant."

vesting commencement date financial

"The option vests based on the first anniversary of the vesting commencement date."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

annual meeting of shareholders financial

"The option vests fully by the registrant's 2027 annual meeting of shareholders."

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

Common Shares financial

"The underlying security title for the option is identified as Common Shares."

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/17/2026 - 05:43 PM Accepted by SEC EDGAR 06/17/2026 - 05:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRUNK GERALD A

(Last) (First) (Middle)

C/O 4868 RUE LEVY, SUITE 220

(Street)

SAINT-LAURENT H4R 2P1

(City) (State) (Zip)

QUEBEC, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
enGene Therapeutics Inc. [ ENGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.75	06/16/2026		A		31,000		(1)	06/16/2036	Common Shares	31,000	$0	31,000	D

Explanation of Responses:

1. This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.

	/s/ Alex J. Nichols, as attorney-in-fact for the Reporting Person	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did enGene Therapeutics (ENGN) report for Gerald A. Brunk?

enGene Therapeutics reported a stock option grant to director Gerald A. Brunk for 31,000 common shares. The options were awarded at no cost, giving him the right to buy shares at a set price in the future.

What is the exercise price of the new enGene (ENGN) stock options?

The new stock options granted to Gerald A. Brunk have an exercise price of $1.75 per share. This is the price he must pay per share if he chooses to exercise the options and convert them into common shares.

When do Gerald A. Brunk’s enGene (ENGN) options vest and become exercisable?

The option vests fully on the earlier of the first anniversary of the June 9, 2026 vesting commencement date or enGene’s 2027 annual meeting of shareholders. Once vested, the 31,000 options can be exercised at the stated price.

When do the stock options granted to enGene (ENGN) director Gerald A. Brunk expire?

The stock options granted to Gerald A. Brunk expire on June 16, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase enGene common shares.

How many enGene (ENGN) options does Gerald A. Brunk hold after this Form 4 transaction?

After this transaction, Gerald A. Brunk holds options for 31,000 common shares directly. This figure reflects his total stock option position reported in the filing following the new grant on June 16, 2026.